InDex Pharmaceuticals Holding AB
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From InDex Pharmaceuticals Holding AB
Servier To Refresh Neuroscience Space With New RNA-Oriented Precision Medicine Focus
The French firm’s stagnant neuroscience franchise will be revamped through a new, strategic focus on RNA-based precision medicines for neurodegenerative diseases including both small- and large-molecule drugs, the company tells Scrip.
Deal Watch: BMS Backs Out Of UniQure Gene Therapy Collaboration
The gene therapy firm announced that Bristol terminated a collaboration started in 2015. Nona follows its recent alliance with Moderna with a second collaboration, this time with Dragonfly.
Finance Watch: Neuron23 Adds $100m To Take First Drug Into The Clinic
Private Company Edition: Westlake Village BioPartners-founded Neuron23 will take the LRRK2 inhibitor NEU-723 for Parkinson’s disease into human testing before the end of 2022. Also, Celsius raised $83m in fresh VC cash and ITM added another €33m to its recent €25m equity financing.
InDex To Fly Solo With Ulcerative Colitis Drug In US
Approval is unlikely before 2027 but Sweden’s InDex has done the maths and decided that it can launch cobitolimod across the Atlantic on its own with a staff of around 100.
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Diagnostic Imaging Equipment & Supplies
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Antisense, Oligonucleotides
- Large Molecule
Drug Discovery Tools
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.